Biodelivery Sciences International Aktie [WKN: 766464 / ISIN: US09060J1060]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Biodelivery Sciences International IncShs

01.03.22		SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates SJI, OBNK, CTXS, BDSI (PR Newswire)
22.02.22		SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FLOW, BDSI, CHWA, DNAA, CCMP (PR Newswire)
15.02.22		SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BDSI, ZWS, NLIT, SPK, SWAG (PR Newswire)
14.02.22		Collegium Pharma To Acquire BioDelivery Sciences International - Quick Facts (RTTNews)
04.08.21		Dr. Reddy's Labs To Sell U.S. And Canada Territory Rights For ELYXYB 25 Mg/mL To BioDelivery (RTTNews)
18.05.18		EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens (RTTNews)
15.05.18		ALL Eyes On PRPH, TNDM Soars On Analyst Upgrade, OMER Back In Focus (RTTNews)
02.05.18		SPX FLOW Reports First Quarter 2018 Results (PR Newswire)
24.04.18		Worldwide Express Ranked as 41st Largest Logistics Provider and 5th Largest Freight Brokerage in North America (PR Newswire)
27.11.17		BioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to Formulary (PR Newswire)
16.11.17		BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference (PR Newswire)
09.11.17		BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
03.11.17		Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences International, Inc. (NASDAQ:BDSI) (PR Newswire)
30.10.17		BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9 (PR Newswire)
24.10.17		EdR Celebrates Grand Opening of On-Campus Housing at Boise State University (PR Newswire)
19.10.17		Genuine Parts Company Reports Sales and Earnings for The Third Quarter Ended September 30, 2017 (PR Newswire)
13.10.17		ONCE Sparkles, BDSI Makes Peace, Coming Event Casts Its Shadow Before ATRS (RTTNews)
06.10.17		BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence (PR Newswire)
19.09.17		BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference (PR Newswire)
12.09.17		BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment (PR Newswire)
24.08.17		BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference (PR Newswire)
23.08.17		BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman (PR Newswire)
17.08.17		Analyzing the Financial Health of Biotech Companies (PR Newswire)
17.08.17		Analyzing the Financial Health of Biotech Companies (PR Newswire)
17.08.17		BioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017 (PR Newswire)
09.08.17		BioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
01.08.17		Technical Reports on Biotech Equities -- BioDelivery Sciences, BioLine Rx, Benitec Biopharma, and Soligenix (PR Newswire)
31.07.17		BioDelivery Sciences Publishes Shareholder Letter with Mid-Year Corporate Update (PR Newswire)
28.07.17		/C O R R E C T I O N -- BioDelivery Sciences International, Inc./ (PR Newswire)
27.07.17		BancorpSouth, Inc. Announces Corporate Entity Restructuring (PR Newswire)
12.07.17		BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) For The Licensing And Distribution Rights Of BELBUCA® In Canada (PR Newswire)
21.06.17		BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA® and BUNAVAIL® Through 2020 (PR Newswire)
06.06.17		Biotech Stock Performance Review -- Cellect Biotechnology, BioDelivery Sciences, BioLine Rx, and Benitec Biopharma (PR Newswire)
01.06.17		BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair 2017 Growth Stock Conference (PR Newswire)
16.05.17		/C O R R E C T I O N -- BioDelivery Sciences International, Inc./ (PR Newswire)
09.05.17		BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial Results on Monday, May 15 (PR Newswire)
02.05.17		BioDelivery Sciences Announces the Approval of BUNAVAIL® for Induction of Buprenorphine Treatment for Opioid Dependence (PR Newswire)
26.04.17		BioDelivery Sciences to Present at the Deutsche Bank 42nd Annual Health Care Conference (PR Newswire)
25.04.17		Research Reports Coverage on Biotech Stocks -- Novan, Stemline Therapeutics, BioDelivery Sciences, and OncoGenex Pharma (PR Newswire)
31.03.17		BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Further Extending and Strengthening Patent Protection on BELBUCA®, BUNAVAIL® and ONSOLIS® (PR Newswire)
24.03.17		Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma (PR Newswire)
17.03.17		BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results (PR Newswire)
16.03.17		BioDelivery Sciences Announces Three Data Presentations on BELBUCA® at the American Academy of Pain Medicine 33rd Annual Meeting (PR Newswire)
09.03.17		BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2016 Financial Results on Friday, March 17 (PR Newswire)
08.03.17		BioDelivery Sciences to Present at the 29th Annual ROTH Conference (PR Newswire)
26.01.17		BioDelivery Sciences to Hold Analyst and Investor Day to Discuss BELBUCA® Commercialization Plans on February 1st in New York City (PR Newswire)
24.01.17		Research Reports Coverage on Biotech Stocks -- Genetic Technologies, Alder Biopharma, BioDelivery Sciences, and Egalet (PR Newswire)
09.01.17		BioDelivery Sciences Closes Transaction to Reacquire License to BELBUCA® from Endo Pharmaceuticals (PR Newswire)
14.12.16		BioDelivery Sciences Announces the Hiring of Peter Ginsberg as Vice President of Business Development (PR Newswire)
13.12.16		BioDelivery Sciences Announces Clonidine Topical Gel for Painful Diabetic Neuropathy Phase 2b Trial Fails to Meet its Primary Efficacy Endpoint (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 15:47
Kaufwert:	EUR
	Hinzufügen Speichern